The isoflavone intake and ecole production ability as a prostate cancer risk ; double blind placebo study

Not Applicable

• Conditions: Prostate cancer

• Registration Number: JPRN-C000000446
• Lead Sponsor: Graduate School of Comprehensive Human Sciences, University of Tsukuba

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2006-07-10
• Study Completion: 2009-09-01
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: Male
• Target Recruitment: 280

Inclusion Criteria

Not provided

Exclusion Criteria

1. History of a prostate cancer 2. High grade PIN in the prostate needle biopsy 3. Past history of surgery of the prostate(transurethral resection, balloon dilation, hyperthermia, stenting et al.) 4. Past history of malignant disease within 5 years other than basal cell carcinoma or squamous cell carcinoma of the skin. 5. The myocardial infarction, coronary artery bypass,unstable angina, arrhythmia, congestive heart failure, cerebral ischemia, uncontrolled diabetes or controlled peptic ulcer. 6. Abnormalities of liver function; more than double level of AST, ALT or ALP, time and a half level of bilirubin. 7. Abnormalities of renal function; more than time and a half level of creatinin. 8. Combined use or use within 12 months of the following drugs; 5 alpha-reductase inhibitor, steroid hormone, anti-androgens (fultamide, bicalutamide, chlormadinone acetate, estrogen, progesterone).anti-androgen action.

Study & Design

• Study Type: Interventional
• Study Design: Not specified